Çukurova University, Adana, Turkey.
İnönü University, Malatya, Turkey.
Int J Clin Pract. 2021 Feb;75(2):e13593. doi: 10.1111/ijcp.13593. Epub 2020 Dec 12.
Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important.
To evaluate the serum levels of three inflammation markers in relation to survival in HCC patients.
We retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival.
Survival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3-fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors.
Combinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.
肝细胞癌与多种慢性炎症性疾病有关。人们越来越认识到,炎症可能是致癌过程的一部分,具有重要的预后意义。
评估三种炎症标志物在 HCC 患者生存中的血清水平。
我们回顾性地检查了 CRP、白蛋白和 ESR 的血清水平,分别和联合检测,以评估患者的生存情况。
CRP 或 ESR 升高或白蛋白水平降低,生存情况恶化。CRP 加白蛋白或 CRP 加 ESR 的组合与更广泛的生存范围(3 倍)相关,最大肿瘤直径(PVT)和门静脉血栓形成(PVT)患者比例也有显著差异。CRP 加白蛋白加 ESR 的三联体与生存的 7 倍差异相关,比较低参数水平与高参数水平。这些显著差异在大小肿瘤的患者中均存在。
CRP 与白蛋白或 ESR 或三者联合检测,与 HCC 大小不同患者的生存差异以及 MTD 和 PVT 比例差异显著相关。